The impact of systemic therapy following ductal carcinoma in situ

J Natl Cancer Inst Monogr. 2010;2010(41):200-3. doi: 10.1093/jncimonographs/lgq021.

Abstract

Following local therapy for ductal carcinoma in situ (DCIS), tamoxifen reduces the risk of ipsilateral and contralateral breast cancer by 30%-50%. Studies of tamoxifen in women with resected DCIS have not shown any effect on overall or cancer-specific survival. The adverse event profile of tamoxifen is well characterized, and individual risks and benefits should be assessed to guide decision making. We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Breast Neoplasms / radiotherapy
  • Breast Neoplasms / surgery
  • Carcinoma, Intraductal, Noninfiltrating / drug therapy*
  • Carcinoma, Intraductal, Noninfiltrating / epidemiology
  • Carcinoma, Intraductal, Noninfiltrating / mortality
  • Carcinoma, Intraductal, Noninfiltrating / pathology
  • Carcinoma, Intraductal, Noninfiltrating / radiotherapy
  • Carcinoma, Intraductal, Noninfiltrating / surgery
  • Chemotherapy, Adjuvant*
  • Clinical Trials, Phase III as Topic / statistics & numerical data
  • Combined Modality Therapy
  • Endometrial Neoplasms / chemically induced
  • Estrogens*
  • Female
  • Follow-Up Studies
  • Humans
  • Mastectomy, Segmental
  • Middle Aged
  • Multicenter Studies as Topic / statistics & numerical data
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Recurrence, Local / prevention & control*
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Neoplasms, Hormone-Dependent / epidemiology
  • Neoplasms, Hormone-Dependent / mortality
  • Neoplasms, Hormone-Dependent / pathology
  • Neoplasms, Hormone-Dependent / radiotherapy
  • Neoplasms, Hormone-Dependent / surgery
  • Neoplasms, Second Primary / epidemiology
  • Neoplasms, Second Primary / prevention & control*
  • Radiotherapy, Adjuvant
  • Randomized Controlled Trials as Topic / statistics & numerical data
  • Receptors, Estrogen / analysis
  • Risk Assessment
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / therapeutic use*
  • Tamoxifen / adverse effects
  • Tamoxifen / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Estrogens
  • Receptors, Estrogen
  • Selective Estrogen Receptor Modulators
  • Tamoxifen